Confronto

TB-500 vs. Thymosin Beta-4

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Guarigione

N. CAS

nessun dato

77591-33-4

Peso molecolare

888 g/mol

4921 g/mol

Emivita

nessun dato

Sequenza

Ac-LKKTETQ

Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES

Meccanismo d'azione

TB-500

Synthetic fragment of the endogenous protein Thymosin Beta-4. In preclinical models, an influence on cell migration, actin sequestration and neovascularisation has been described. Robust human pharmacokinetic data are not publicly available.

Thymosin Beta-4

Thymosin Beta-4 forms a 1:1 complex with monomeric (G-)actin and is regarded as the principal actin-sequestering factor in many cell types, thereby influencing cytoskeletal dynamics and directional cell migration. Preclinical models additionally describe effects on endothelial cell migration and neovascularisation, as well as activation of survival signalling pathways (including ILK/Akt). The mechanistic evidence derives predominantly from cell-culture and animal models.

Base di evidenze

Evidenza più alta

Modello animale

Studio sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	TB-500	Thymosin Beta-4
Australia	Vietato	—
Germania	Non approvato	Non approvato
Stati Uniti	Solo ricerca	Non approvato

Voci complete

Frequently asked questions

What is the difference between TB-500 and Thymosin Beta-4?: TB-500 is classified as "Guarigione", while Thymosin Beta-4 is classified as "Guarigione". TB-500: Synthetic fragment of the endogenous protein Thymosin Beta-4, specifically the actin-binding sequence. Preclinical models investigate effects on cell migration, neovascularisation and wound healing — robust human data are absent. Thymosin Beta-4: Thymosin Beta-4 (Tβ4) is an endogenous 43-amino-acid peptide regarded as the principal intracellular actin-sequestering factor, involved in cell migration, neovascularisation and tissue regeneration. It has been studied in dry eye, corneal and wound healing, and cardiac repair (RegeneRx programmes, RGN-259). Thymosin Beta-4 is NOT an approved drug; robust human efficacy data are limited. The grey-market TB-500 is a synthetic fragment/analogue and is distinct from it. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, TB-500 or Thymosin Beta-4?: The highest available evidence level is "Modello animale" for TB-500 and "Studio sull'uomo" for Thymosin Beta-4. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of TB-500 and Thymosin Beta-4 in Germany and the United States?: Germania: TB-500 — Non approvato, Thymosin Beta-4 — Non approvato. Stati Uniti: TB-500 — Solo ricerca, Thymosin Beta-4 — Non approvato. These are factual summaries with source and review date on the individual pages.

Country

TB-500

Thymosin Beta-4

Australia

Vietato

—

Germania

Non approvato

Stati Uniti

Solo ricerca

Non approvato

Frequently asked questions

What is the difference between TB-500 and Thymosin Beta-4?

TB-500 is classified as "Guarigione", while Thymosin Beta-4 is classified as "Guarigione". TB-500: Synthetic fragment of the endogenous protein Thymosin Beta-4, specifically the actin-binding sequence. Preclinical models investigate effects on cell migration, neovascularisation and wound healing — robust human data are absent. Thymosin Beta-4: Thymosin Beta-4 (Tβ4) is an endogenous 43-amino-acid peptide regarded as the principal intracellular actin-sequestering factor, involved in cell migration, neovascularisation and tissue regeneration. It has been studied in dry eye, corneal and wound healing, and cardiac repair (RegeneRx programmes, RGN-259). Thymosin Beta-4 is NOT an approved drug; robust human efficacy data are limited. The grey-market TB-500 is a synthetic fragment/analogue and is distinct from it. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, TB-500 or Thymosin Beta-4?

The highest available evidence level is "Modello animale" for TB-500 and "Studio sull'uomo" for Thymosin Beta-4. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of TB-500 and Thymosin Beta-4 in Germany and the United States?

Germania: TB-500 — Non approvato, Thymosin Beta-4 — Non approvato. Stati Uniti: TB-500 — Solo ricerca, Thymosin Beta-4 — Non approvato. These are factual summaries with source and review date on the individual pages.